000 01439 a2200421 4500
005 20250515011329.0
264 0 _c20061026
008 200610s 0 0 eng d
022 _a0960-9822
024 7 _a10.1016/j.cub.2005.11.059
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aMorrison, Paul D
245 0 0 _aSchizophrenia.
_h[electronic resource]
260 _bCurrent biology : CB
_cDec 2005
300 _aR980-4 p.
_bdigital
500 _aPublication Type: Journal Article; Review
650 0 4 _aAntipsychotic Agents
_xtherapeutic use
650 0 4 _aBrain
_xanatomy & histology
650 0 4 _aCarrier Proteins
_xgenetics
650 0 4 _aChlorpromazine
_xtherapeutic use
650 0 4 _aClozapine
_xtherapeutic use
650 0 4 _aDopamine
_xmetabolism
650 0 4 _aDopamine Antagonists
_xtherapeutic use
650 0 4 _aDysbindin
650 0 4 _aDystrophin-Associated Proteins
650 0 4 _aGenetic Predisposition to Disease
650 0 4 _aHumans
650 0 4 _aMagnetic Resonance Imaging
650 0 4 _aModels, Neurological
650 0 4 _aNerve Tissue Proteins
_xgenetics
650 0 4 _aNeuregulin-1
_xgenetics
650 0 4 _aSchizophrenia
_xdrug therapy
650 0 4 _aSocial Alienation
650 0 4 _aSynapses
_xmetabolism
700 1 _aMurray, Robin M
773 0 _tCurrent biology : CB
_gvol. 15
_gno. 24
_gp. R980-4
856 4 0 _uhttps://doi.org/10.1016/j.cub.2005.11.059
_zAvailable from publisher's website
999 _c15980718
_d15980718